Brokerage Firm Rating Update on PDL BioPharma (PDLI)

PDL BioPharma (PDLI) has an average broker rating of 3, which is interpreted as a Hold, as rated by 2 equity analysts. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

PDL BioPharma (PDLI) stock is expected to deviate a maximum of $0.35 from the average target price of $3.75 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $4 and the most muted being $4.


Company shares have received an average consensus rating of Hold for the current week

PDL BioPharma (NASDAQ:PDLI): The stock was completely flat for the day, closing at $3.24 on Wednesday. The flat closing masks the intraday volatility in the stock. After opening at $3.19, the stock touched an intraday high of $3.24 and a low of $3.13. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $3.24. The total trading volume on Wednesday was 1,979,095.

PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *